| pubmed-article:9554538 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0017687 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0020615 | lld:lifeskim |
| pubmed-article:9554538 | lifeskim:mentions | umls-concept:C0011900 | lld:lifeskim |
| pubmed-article:9554538 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:9554538 | pubmed:dateCreated | 1998-4-29 | lld:pubmed |
| pubmed-article:9554538 | pubmed:abstractText | Tumor hypoglycemia can be recurrent and severe enough to interfere with definitive antineoplastic treatment. Therefore, rapid commencement of effective therapy is essential. This is best accomplished by identifying which of the hypoglycemic processes is involved, as treatments differ. Some patients present with hypoglycemia and liver metastases; among them, only a few develop hypoglycemia as a result of a failure of hepatic glucose production. Most develop hypoglycemia as a result of an insulin-mediated process--either the secretion of insulin by an islet-cell tumor or the secretion of insulin-like growth factor-II by an extrapancreatic tumor. Administration of glucagon can rapidly make the two groups distinguishable, thus allowing institution of therapy and prompt symptomatic control of hypoglycemia. | lld:pubmed |
| pubmed-article:9554538 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9554538 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9554538 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9554538 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9554538 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9554538 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9554538 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9554538 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:9554538 | pubmed:author | pubmed-author:Vassilopoulou... | lld:pubmed |
| pubmed-article:9554538 | pubmed:author | pubmed-author:LAMYJ LJL | lld:pubmed |
| pubmed-article:9554538 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9554538 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9554538 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:9554538 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9554538 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9554538 | pubmed:pagination | 1585-92 | lld:pubmed |
| pubmed-article:9554538 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:meshHeading | pubmed-meshheading:9554538-... | lld:pubmed |
| pubmed-article:9554538 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9554538 | pubmed:articleTitle | The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. | lld:pubmed |
| pubmed-article:9554538 | pubmed:affiliation | Section of Endocrine Neoplasia and Hormonal Disorders, Baylor College of Medicine, Houston, Texas, USA. | lld:pubmed |
| pubmed-article:9554538 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9554538 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9554538 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9554538 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9554538 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9554538 | lld:pubmed |
